|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:activities
|
inhibits cell proliferation
|
|
gptkbp:class
|
gptkb:drug
|
|
gptkbp:clinical_trial
|
high
ongoing
Phase 1
Phase 2
multiple sites
promising efficacy
|
|
gptkbp:collaborations
|
University of Medicine
|
|
gptkbp:composed_of
|
multi-step synthesis
|
|
gptkbp:criteria
|
promising
|
|
gptkbp:developed_by
|
gptkb:Alchem_Laboratories
|
|
gptkbp:dissolved
|
soluble in DMSO
slightly soluble in water
|
|
gptkbp:dosage_form
|
once daily
|
|
gptkbp:field_of_study
|
oncology
|
|
gptkbp:formulation
|
gptkb:tablet
injectable
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ALX-0727
|
|
gptkbp:ingredients
|
C20 H22 N4 O3 S
|
|
gptkbp:interacts_with
|
none reported
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_tested_for
|
clinical trials
|
|
gptkbp:is_used_for
|
treatment of cancer
|
|
gptkbp:lifespan
|
12 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:market
|
not yet marketed
|
|
gptkbp:population
|
adults
|
|
gptkbp:products
|
IND-123456
|
|
gptkbp:publishes
|
gptkb:Pharmaceutical_Sciences_Journal
gptkb:Clinical_Oncology_Journal
gptkb:Journal_of_Cancer_Research
Cancer Chemotherapy Reports
Oncology Reviews
|
|
gptkbp:receives_funding_from
|
private investment
government grant
|
|
gptkbp:regulatory_compliance
|
pending
|
|
gptkbp:research
|
successful
|
|
gptkbp:research_areas
|
gptkb:healthcare_organization
oncology
|
|
gptkbp:rounds
|
renal
|
|
gptkbp:safety_features
|
acceptable
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
liver toxicity
kidney toxicity
|
|
gptkbp:social_structure
|
contains a sulfonamide group
|
|
gptkbp:targets
|
tumor cells
|
|
gptkbp:treatment
|
gptkb:battle
|
|
gptkbp:type_of
|
123456-78-9
|
|
gptkbp:weight
|
398.48 g/mol
|
|
gptkbp:year_created
|
gptkb:2020
|
|
gptkbp:bfsParent
|
gptkb:Ablynx
|
|
gptkbp:bfsLayer
|
4
|